The Trump administration’s recent crackdown on direct-to-consumer (DTC) drug advertising got me thinking. I’m of an age where the shows I watch on television or stream are rife with DTC advertising for diabetes drugs and biologics to treat autoimmune disease, rare disease, macular degeneration, and other ophthalmologic disorders. I was never a fan of DTC … Continue reading DTC Advertising and the Biosimilar Opportunity